

## **COBRED** **Colon and Breast** **cancer Diagnostics**

is a European research project that aims at discovering colon cancer and breast cancer biomarkers for patient follow-up (monitoring markers) by exploiting the capacity of 3 state-of-the-art high-throughput technologies in an integrated systems biology approach.



## THE SPECIFIC RTD OBJECTIVES ARE:

- 1 TO DESIGN** a clinical protocol for prospective clinical BC and CRC collections that fit the needs of the 3 high-throughput screening technologies used: transcriptomics, proteomics and metabolomics,
- 2 TO IDENTIFY** biomarker candidates (metabolites, proteins, PBL derived mRNAs) capable to detect and assess the status of minimal residual disease, metastases and recurrence after surgery and chemotherapy,
- 3 TO DEVELOP** a centralized database to integrate the data generated by the 3 technology platforms with the anatomoclinical information of the clinical collections,
- 4 TO DISCOVER** biomarkers with better specificity and sensitivity using across-platform advance datamining techniques on the combined data from the consolidated database,
- 5 TO VALIDATE** the biological relevance and diagnostic potential of the identified biomarkers by testing their specificity on tissue arrays and in relevant preclinical models.

To this aim, **the project assembles for a period of three years a European consortium of distinguished scientists** from **three biotech** pioneer SMEs with expertise in genomics, proteomics and metabolomics, **three leading universities** and **two clinical institutes** renowned for their expertise in colon cancer and breast cancer treatment.

## WHY DOES COBRED FOCUS ON BREAST AND COLON CANCER?

**Breast cancer is the most common cancer in European women** and **colorectal cancer is the third most common cancer type worldwide**, diagnostics based on biomarkers have the potential to significantly improve current cancer disease management and diagnosis, providing higher sensitivity at a lower cost thus leading to a direct benefit to patients and society.


## WHAT WILL COBRED DELIVER?

**A set of biomarker / diagnostic candidates** verified in preclinical studies, ready for large scale clinical validation

**A demonstration of the potential** to explore consolidated data resulting from three different high-throughput technologies and clinical profiles with advanced data mining technologies for enhanced biomarker discovery.

**Data gathered** to study yet poorly understood cancer mechanisms.

...





## **THE COBRED PARTNERS ARE:**

**BioSystems International, France**  
**Biocrates, Austria**  
**Ipsogen, France**  
**Institut Curie, France**  
**Institut Gustave-Roussy, France**  
**University of Debrecen, Hungary**  
**University of Innsbruck, Austria**  
**University of Tartu, Estonia**  
**ARTTIC, France**



*Supported by the Life-Science-Health Programme Sixth  
EU Framework Programme for Research and Technological  
Development with a funding contribution of K€ 2.985,-.*

For further information and contacting the partners, please visit

**[www.cobred.eu](http://www.cobred.eu)**

or contact **the Coordinator**

**Dr. Laszlo Takacs** Biosystems International

Tel.: +33 1 60 87 89 75

Email: laszlo.takacs@biosys-intl.com



## THE COBRED PARTNERS ARE:

**BioSystems International**, France  
**Biocrates**, Austria  
**Ipsogen**, France  
**Institut Curie**, France  
**Institut Gustave-Roussy**, France  
**University of Debrecen**, Hungary  
**University of Innsbruck**, Austria  
**University of Tartu**, Estonia  
**ARTTIC**, France



*Supported by the Life-Science-Health Programme Sixth  
EU Framework Programme for Research and Technological  
Development with a funding contribution of K€ 2.985,-.*

For further information and contacting the partners, please visit

**[www.cobred.eu](http://www.cobred.eu)**

or contact **the Coordinator**

**Dr. Laszlo Takacs** Biosystems International

Tel.: +33 1 60 87 89 75

Email: laszlo.takacs@biosys-intl.com

## COBRED Colon and Breast cancer Diagnostics

is a European research project that aims at discovering colon cancer and breast cancer biomarkers for patient follow-up (monitoring markers) by exploiting the capacity of 3 state-of-the-art high-throughput technologies in an integrated systems biology approach.

**[www.cobred.eu](http://www.cobred.eu)**